Roth Boosts PT on Concert Pharma (CNCE) to $22 Following; Deuterium Platform, Partnerships Will Bolster Gains

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. SKA-B
5. PBA
6. CCH:LN
7. META
8. CCHGY
9. PRY:IM
10. PRYMY

Go back to Roth Boosts PT on Concert Pharma (CNCE) to $22 Following; Deuterium Platform, Partnerships Will Bolster Gains

Concert Pharmaceuticals Reports First Quarter 2015 Financial Results

May 8, 2015 7:00 AM EDT

Conference Call Scheduled Today at 8:30 a.m. EDT

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2015.

Concert ended the first quarter with a strong balance sheet and the financial resources to continue advancing our portfolio of product candidates, said Roger Tung,... More

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

May 7, 2015 4:05 PM EDT

Phase 1 Results Support Further Evaluation of JZP-386

DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)-- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)... More